Abstract:Background: T cells exhibit heterogeneous functional states in the tumor microenvironment. Immune checkpoint inhibitors (ICIs) can reinvigorate only the stem cell-like progenitor exhausted T cells, which suggests that inhibiting the exhaustion progress will improve the efficacy of immunotherapy. Thus, regulatory factors promoting T cell exhaustion could serve as potential targets for delaying the process and improving ICI efficacy. Methods: We analyzed the single-cell transcriptome data derived from human melanoma and non-small cell lung cancer (NSCLC) samples and classified the tumor-infiltrating (TI) CD8+ T cell population based on PDCD1 (PD-1) levels, i.e., PDCD1-high and PDCD1-low cells. Additionally, we identified differentially expressed genes as candidate factors regulating intra-tumoral T cell exhaustion. The co-expression of candidate genes with immune checkpoint (IC) molecules in the TI CD8+ T cells was confirmed by single-cell trajectory and flow cytometry analyses. The loss-of-function effect of the candidate regulator was examined by a cell-based knockdown assay. The clinical effect of the candidate regulator was evaluated based on the overall survival and anti-PD-1 responses. Results: We retrieved many known factors for regulating T cell exhaustion among the differentially expressed genes between PDCD1-high and PDCD1-low subsets of the TI CD8+ T cells in human melanoma and NSCLC. TOX was the only transcription factor (TF) predicted in both tumor types. TOX levels tend to increase as CD8+ T cells become more exhausted. Flow cytometry analysis revealed a correlation between TOX expression and severity of intra-tumoral T cell exhaustion. TOX knockdown in the human TI CD8+ T cells resulted in downregulation of PD-1, TIM-3, TIGIT, and CTLA-4, which suggests that TOX promotes intra-tumoral T cell exhaustion by upregulating IC proteins in cancer. Finally, the TOX level in the TI T cells was found to be highly predictive of overall survival and anti-PD-1 efficacy in melanoma and NSCLC. Conclusions: We predicted the regulatory factors involved in T cell exhaustion using single-cell transcriptome profiles of human TI lymphocytes. TOX promoted intra-tumoral CD8+ T cell exhaustion via upregulation of IC molecules. This suggested that TOX inhibition can potentially impede T cell exhaustion and improve ICI efficacy. Additionally, TOX expression in the TI T cells can be used for patient stratification during anti-tumor treatments, including anti-PD-1 immunotherapy.

Increased TOX Expression Concurrent with PD-1, Tim-3, and CD244 in T Cells from Patients with Non-Hodgkin Lymphoma.

Increased TOX Expression Associates with Exhausted T Cells in Patients with Multiple Myeloma

Increased TOX Expression Concurrent with PD-1, Tim-3, and CD244 Expression in T Cells from Patients with Acute Myeloid Leukemia.

TOX Promotes the Exhaustion of Antitumor CD8(+) T Cells by Preventing PD1 Degradation in Hepatocellular Carcinoma

Higher TOX Genes Expression is Associated with Poor Overall Survival for Patients with Acute Myeloid Leukemia.

The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma

Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer

Different Aberrant Expression Pattern of Immune Checkpoint Receptor in Patients with T-NHL and NK/T-CL

TNFR2 loss leads to decreased TOX expression in T cells without affecting TIM3 and improves responses to tumor and chronic LCMV

Characteristics of PD-1, TIM-3 Expression and Exhausted Phenotype in T Cells from Peripheral Blood and Bone Marrow in Patients with AML

TOX is a critical regulator of tumour-specific T cell differentiation

TOX As a Potential Target for Immunotherapy in Lymphocytic Malignancies

Tumor-derived Exosomes Induce Initial Activation by Exosomal CD19 Antigen but Impair the Function of CD19-specific CAR T-cells Via TGF-β Signaling.

IL-10 Induces the Development of Immunosuppressive CD14 + HLA-DR Low/− Monocytes in B-cell Non-Hodgkin Lymphoma

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations

[CD4+ CD25high Regulatory T Cells in Peripheral Blood of Patients with B Cell Non-Hodgkin's Lymphoma].

T-cell Exhaustion Interrelates with Immune Cytolytic Activity to Shape the Inflamed Tumor Microenvironment.

Increased Exhausted CD8(+) T Cells with Programmed Death-1, T-cell Immunoglobulin and Mucin-Domain-containing-3 Phenotype in Patients with Multiple Myeloma

Long Non-Coding RNA Lnc-Tim3 Exacerbates CD8 T Cell Exhaustion Via Binding to Tim-3 and Inducing Nuclear Translocation of Bat3 in HCC.

Higher Tim-3 expression concurrent with PD-1 in exhausted CD4+ and CD8+T cells in patients with acute myeloid leukemia